Trial Profile
Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 21 Mar 2022 Status changed from active, no longer recruiting to completed.
- 17 Dec 2021 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology